01—Abstract
Summary
Summary of the 8-K filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals reported Q2 2024 results that were dominated by a one-time charge tied to its acquisition of Alpine Immune Sciences.
Product revenue rose 6% year over year to $2.65 billiona, led by TRIKAFTA/KAFTRIO, with U.S. net product revenue up 7% to $1.61 billion and ex-U.S. up 5% to $1.03 billion. However, Acquired IPR&D expense jumped to $4.4 billion (versus $111 million a year earlier), producing a GAAP net loss of $3.6 billion, or $(13.92) per diluted share, compared with net income of $916 million in Q2 2023. Non-GAAP net loss was $3.3 billion, or $(12.83) per share.
Management raised full-year 2024 product revenue guidance to $10.65b-$10.85 billion from $10.55-$10.75 billion. The company now expects combined GAAP R&D and SG&A of $5.0-$5.2 billion, and AIPR&D expense of about $4.6 billion, with a non-GAAP effective tax rate near 100% because the Alpine charge is non-deductible. Cash, equivalents and marketable securities fell to $10.2 billion from $13.7 billion, reflecting roughly $5.0 billion of cash paid for Alpine.
The filing also highlights regulatory momentum. The FDA accepted the vanzacaftor triple NDA (PDUFA January 2, 2025) and suzetrigine NDA (PDUFA January 30, 2025), both with Priority Review. Investors should weigh the strong revenue trajectory and pipeline catalysts against the sharp near-term earnings and tax-rate distortion, and the reduced cash cushion, while recognizing that the AIPR&D charge is a non-cash-like accounting event tied to the Alpine deal.
02—Key points
Key Highlights
- Product revenue grew 6% to $2.65 billion in Q2 2024, with TRIKAFTA/KAFTRIO at $2.45 billion (up 9% year over year).
- Acquired IPR&D expense of $4.4 billion from the Alpine Immune Sciences acquisition drove a GAAP net loss of $3.6 billion, or $(13.92) per diluted share, versus net income of $916 million a year earlier.
- Full-year 2024 product revenue guidance raised to $10.65-$10.85 billion from $10.55-$10.75 billion, with CASGEVY launch contributions included.
- Full-year AIPR&D expense guidance is about $4.6 billion, and the non-GAAP effective tax rate is expected to be near 100% because the Alpine charge is non-deductible.
- Cash, cash equivalents and marketable securities declined to $10.2 billion from $13.7 billion at year-end 2023, largely due to the Alpine cash consideration of about $5.0 billion.
- FDA accepted the vanzacaftor triple NDA (PDUFA January 2, 2025) and suzetrigine NDA (PDUFA January 30, 2025), both under Priority Review, setting up key 2025 catalysts.
- Other pipeline milestones include the povetacicept Phase 3 RAINIER trial in IgA nephropathy, the suzetrigine Phase 3 DPN program, and the VX-880 type 1 diabetes study expansion to 37 patients.
03—Questions
Frequently Asked Questions
Why did Vertex post a large net loss in Q2 2024 after reporting profits a year earlier?
The loss was driven by a $4.4 billion non-cash-like Acquired IPR&D charge tied to the acquisition of Alpine Immune Sciences, which included its lead asset povetacicept. Excluding this charge and related adjustments, the business continued to grow, with product revenue up 6%.
Is the underlying business still growing?
Yes. Product revenue rose 6% to $2.65 billion, U.S. revenue grew 7%, and ex-U.S. revenue grew 5%. Management raised full-year product revenue guidance, citing continued CF growth in younger age groups and the CASGEVY launch.
Why is the non-GAAP tax rate so unusual for 2024?
The Alpine AIPR&D expense is non-deductible for tax purposes. Because it creates a pre-tax loss while still generating tax expense, the full-year non-GAAP effective tax rate is expected to be around 100%, versus roughly 20-21% previously guided.
What near-term catalysts should investors watch?
The FDA decisions on vanzacaftor triple in CF (PDUFA January 2, 2025) and suzetrigine for acute pain (PDUFA January 30, 2025) are the key near-term events. Additional milestones include the suzetrigine lumbosacral radiculopathy Phase 2 results expected in late 2024 and the start of the povetacicept Phase 3 RAINIER trial in IgA nephropathy.
How did the Alpine acquisition affect Vertex's balance sheet and liquidity?
Cash, cash equivalents and marketable securities fell to $10.2 billion at June 30, 2024, from $13.7 billion at year-end 2023. Shareholders' equity declined to $14.8 billion from $17.6 billion, reflecting the large charge.
04—Continue